[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-insufficiency-of-leg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-insufficiency-of-leg":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,73,108,135,155,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100620830","therapeutic-efficacy-of-the-phlebology-oriented-thermal-cure-at-the-saint-eloy-thermal-center-in-the-treatment-of-symptoms-of-severe-chronic-venous-insufficiency-100620830",false,"NCT07362719","Therapeutic Efficacy of the Phlebology-oriented Thermal Cure at the Saint-Eloy Thermal Center in the Treatment of Symptoms of Severe Chronic Venous Insufficiency","AMNEVILLE-PHL","Inclusion Criteria:\n\n* Adult male or female (≥ 18 years of age).\n* Patients with severe chronic venous insufficiency of the lower limbs (C4a,b,c - C5 according to the CEAP (Clinical manifestations, Etiology, Anatomic distibution, Pathophysiology) classification (2020 revision) for at least one of the legs) confirmed by venous Doppler ultrasound of the lower limbs.\n* Patients with an indication for a thermal cure exclusively focused on phlebology.\n* Patients available to participate in a 3-week consecutive thermal cure at the Saint-Eloy Thermal Center, followed by 6 months of clinical follow-up, in accordance with the protocol schedule.\n* Patients available to attend the visits scheduled in the protocol and able to complete the data collection documents.\n* For women of childbearing age: patient using effective contraception.\n* Patient affiliated with a health insurance plan or beneficiary (Art. L.1121-8-1, French Public Health Code).\n* Patient who has given their informed consent in writing regarding their participation in the protocol.\n\nExclusion Criteria:\n\n* Patients with a contraindication to thermal cure.\n* Patients who have participated in thermal cure (regardless of type) within the last 9 months.\n* Patients who have had an ulcer on their lower limbs that has healed within the last 3 months.\n* Patients without venous trophic disorders of the lower limbs, and in particular patients with isolated class C3 chronic venous insufficiency or less in both lower limbs.\n* Patients with an open ulcer on a lower limb (class C6).\n* Patients for whom interventional venous treatment is due to begin within the next 6 months.\n* Patients scheduled to undergo orthopedic surgery on the lower limbs within the next 6 months.\n* Patients who are unable to walk.\n* Patients with a known allergy to sulfur.\n* Patients with any medically significant findings or significant history that may impact safety, interpretation of results, and\u002For subject participation in the study at 6 months, in the investigator's opinion.\n* Patients simultaneously participating in another clinical trial or who have participated in another clinical trial for which the exclusion period has not ended.\n* Vulnerable persons (Art. L.1121-5 to 8, and L1122-1-2, French Public Health Code).","ALL","18 Years",{"count":19,"type":20},84,"ESTIMATED","INTERVENTIONAL",[23],"NA","Chronic venous insufficiency (CVI) is a common progressive vascular disease that affects nearly one-third of the French population. Despite considerable advances in the treatment of chronic venous insufficiency, this condition remains a burden for patients and national healthcare systems.\n\nBalneotherapy-which includes thermal cures-is part of the therapeutic arsenal used in the treatment of chronic venous insufficiency. It is a relatively effective alternative with a relatively low cost compared to drug or surgical treatments. Phlebology is a thermal treatment orientation recognized by the French social security system.\n\nThe Saint-Eloy Thermal Center is listed among the thermal stations approved by the French Ministry of Health. It currently uses thermal water from Amnéville-les-Thermes to treat rheumatological and respiratory conditions, and wants to expand its range of orientations by adding phlebology. The AMNEVILLE-PHL study therefore aims to evaluate the efficacy and safety of the Saint-Eloy thermal cure for phlebology in patients suffering from severe chronic venous insufficiency.",[26],"Venous Insufficiency of Leg",[28,29,30,31,26],"Severe chronic venous insufficiency","Thermal cure","Phlebology","Balneology","RECRUITING","2026-07-17",{"date":35,"type":36},"2026-07-20","ACTUAL",{"date":38,"type":36},"2026-02-27",{"date":40,"type":20},"2027-05",{"name":42,"class":43},"Société d'Exploitation des Thermes d'Amnéville","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":70,"locationsCount":4},"100647022","phase-3-randomized-placebo-crontrolled-clinical-trial-evaluating-the-efficacy-and-safety-of-heparan-sulfate-120-mg-prolonged-release-tablets-compared-with-placebo-in-patients-with-chronic-venous-disease-100647022","NCT07684833","Randomized, Placebo-crontrolled Clinical Trial Evaluating the Efficacy and Safety of Heparan Sulfate 120 mg Prolonged-Release Tablets Compared With Placebo in Patients With Chronic Venous Disease","Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate Efficacy and Safety of CLR-07-23 (Heparan Sulfate 120 mg Prolonged-release Tablets) in the Treatment of Primary Chronic Venous Disease","CLR-18","Inclusion Criteria:\n\n* Participants with an age ≥ 18 and ≤ 80 years\n* Diagnosed primary venous disease of the lower limbs in stage C2 - C5 according to the CEAP classification, involvement of the venous system of the lower limbs is verified by duplex ultrasonography\n* Presence of objective signs and subjective symptoms of the disease (classified according to rVCSS score ≥ 4)\n* Participants not using or planning to use compression therapy by their own decision\n* Provision of written informed consent as approved by the Ethics Committee (EC).\n\nExclusion Criteria:\n\n* Use of a venoactive drug in the last month\n* Regular use of compression therapy or use of mechanical devices for reduction of edema in the last month\n* Heart Failure (NYHA class III and IV), congestive heart failure with peripheral edema\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m² at screening or chronic kidney disease documented in the medical history\n* ALT or AST more than 3 times the upper limit of normal range at screening or advanced liver disease documented in the medical history\n* Deep venous thrombosis lower limb thrombosis and \u002F or documented residual venous obstruction or deep venous reflux due to post-thrombotic alterations in the deep venous system\n* Superficial venous thrombosis of the lower limbs in the previous 6 months\n* Congenital venous\u002Flymphatic malformation\n* Neuropathy of any aetiology\n* Diabetic foot syndrome\n* Refractory (uncontrollable) hypertension (inability to therapeutically achieve a systolic blood pressure ≤ 160 mmHg or a diastolic blood pressure ≤ 100 mmHg)\n* Symptomatic ischemic disease of lower limbs\n* Lymphoedema: primary, posttraumatic, postoperative, post-radiation, malignant\n* Manual\u002Finstrumental lymphatic drainage in the last 3 months\n* Invasive procedure on the lower limbs in the last 6 months\n* Trauma of the lower extremity that has not fully healed\n* Use of oral\u002Fparenteral anticoagulants\n* Use of dual antiplatelet therapy\n* Use of loop diuretics\n* Use of oestrogens or progesterone and its derivates\n\n  -. Use of oral\u002Fparental corticosteroids in the last 6 weeks\n* Chronic pain treatment ≥ 14 days\n* Use of psychopharmaceuticals affecting fluid retention (antipsychotics, combined antidepressants)\n* Severe obesity (BMI \\> 40 kg\u002Fm2)\n* Participants with active malignant disease or malignant disease in remission for less than 5 years\n* Myeloproliferative or immune disorders\n* Contraindications to the IMP\u002FPlacebo administration\n* Hypersensitivity to the IMP\u002FPlacebo excipients. General Conditions\n* Pregnant or breastfeeding women\n* Women of child-bearing potential not using at least one effective contraceptive method for the entire trial\n* Participation in other investigational drug or device clinical trials within 30 days prior to study screening\n\n  -. Participants legally or mentally incapacitated unable to give informed consent for the participation in this trial\n* Participants unable or unwilling to comply with appointments or all protocol requirements.",true,"80 Years",{"count":56,"type":20},174,[58],"PHASE3","This multicenter, randomized, double-blind study is a phase III evaluates the safety and effectiveness of CLR prolonged-release tablets in patients with chronic venous insufficiency, has been shown to be effective in reducing the symptoms of itching, edema, spontaneous pain, and night cramps chronic venous disease.",[61,62,26],"Chronic Venous Disease","Vein Disease","NOT_YET_RECRUITING","2026-06-29",{"date":66,"type":36},"2026-07-06",{"date":68,"type":20},"2026-11",{"date":40,"type":20},{"name":71,"class":72},"Barbara Maglione","INDUSTRY",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100570426","phase-3-tissue-repair-gel-in-venous-leg-ulcers-us-100570426","NCT06707090","Tissue Repair Gel in Venous Leg Ulcers (US)","A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)","TRIVIA","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* Participants considered nutritionally deficient.",{"count":82,"type":20},312,[58],"The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.",[86,87,88,89,90,91,26,92],"Venous Leg Ulcer","Venous Ulcer","Venous Stasis Ulcer","Venous Stasis","Wound Heal","Wounds","Non-healing Wound",[94,95,96,97,98],"Tissue Repair","Glucoprime","TR Therapeutics","Debridement","VLU","2026-02-09",{"date":101,"type":36},"2026-02-12",{"date":103,"type":36},"2025-01-28",{"date":105,"type":20},"2028-02",{"name":96,"class":72},33,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":44},"100596501","clinical-outcomes-safety-and-cost-effectiveness-analysis-of-two-catheters-xianrui-da-and-medtronic-in-radiofrequency-ablation-for-varicose-veins-100596501","NCT07046286","Clinical Outcomes, Safety, and Cost-Effectiveness Analysis of Two Catheters (Xianrui Da and Medtronic) in Radiofrequency Ablation for Varicose Veins","Clinical Outcomes, Safety, and Cost-Effectiveness Analysis of Two Catheters (Xianrui and Medtronic) in Radiofrequency Ablation for Varicose Veins","Inclusion Criteria:\n\n1. Age between 18 and 80 years old.\n2. Clinically diagnosed with primary lower extremity varicose veins, with CEAP grade C2 - C5, and requiring treatment of the great saphenous vein segment.\n3. Doppler ultrasound confirms that the reflux time of the saphenofemoral vein valve is \\> 1.0 second.\n4. Doppler ultrasound confirms that the diameter of the great saphenous vein in the supine position is \\> 3mm and \\\u003C 12mm.\n5. Only one limb of each patient is included in the study.\n6. The patient signs the informed consent form and is willing to cooperate with the examinations and follow - ups specified in the protocol.\n\nExclusion Criteria:\n\n1. Thrombosis in the great saphenous vein, or combined with deep vein thrombosis, or a history of deep vein thrombosis or pulmonary embolism.\n2. Recurrent varicose veins after previous treatment.\n3. Severe tortuosity of the great saphenous vein, with the expectation that the catheter cannot pass through.\n4. Severe lower extremity ischemia (CLI).\n5. Known allergy to drugs or device materials involved in the study.\n6. History of cardiac pacemaker or defibrillator implantation.\n7. Pregnant or breastfeeding women.\n8. Currently participating in other drug or device studies.\n9. Deemed unsuitable for endovenous treatment by the researcher.",{"count":116,"type":20},200,[23],"This study aims to systematically compare the clinical efficacy (venous closure rate and symptom relief rate), safety (perioperative and postoperative complications), and cost-effectiveness (direct medical costs) of domestic Xianruida radiofrequency catheter and imported Medtronic catheter in endovenous radiofrequency ablation for varicose veins through a single-center, prospective, non-inferiority randomized controlled trial.",[120,26,121],"Varicose Veins of Lower Limb","Vascular Disease，Peripheral",[123,124,125],"varicose veins of the great saphenous veins","radiofrequency ablation","catheters","2025-06-29",{"date":128,"type":36},"2025-07-01",{"date":130,"type":20},"2025-08-01",{"date":132,"type":20},"2026-10-01",{"name":134,"class":43},"Chengdu University of Traditional Chinese Medicine",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":78,"acronym":79,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":84,"conditions":143,"keywords":145,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100570427","phase-3-tissue-repair-gel-in-venous-leg-ulcers-in-auus-100570427","NCT06707103","Tissue Repair Gel in Venous Leg Ulcers in AU\u002FUS","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* History of cancer in the preceding 5 years (except as noted in the protocol).\n* Participants considered nutritionally deficient.",{"count":82,"type":20},[58],[86,87,88,89,90,144,26,92],"Wound",[94,95,96,97,98],"2025-03-27",{"date":148,"type":36},"2025-04-02",{"date":150,"type":20},"2025-04",{"date":152,"type":20},"2027-02",{"name":96,"class":72},12,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":44},"100570736","comparative-analysis-of-radiofrequency-ablation-and-microwave-ablation-procedures-for-the-treatment-of-small-saphenous-varicose-veins-100570736","NCT06711120","Comparative Analysis of Radiofrequency Ablation and Microwave Ablation Procedures for the Treatment of Small Saphenous Varicose Veins","Randomized Controlled Study of Radio Frequency and Microwave of the Small Saphenous Vein","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years;\n* Clinical diagnosis of primary varicose veins of the lower extremities, CEAP clinical classification C2-C6, requiring treatment of the great and\u002For small saphenous vein segments, and at least 1 of the clinical symptoms of swelling, pain, burning sensation, heaviness, easy fatigue, itchy skin, and night cramps;\n* Valve insufficiency of the great saphenous vein, small saphenous vein, or transport vein;\n* Doppler ultrasound confirmation of a saphenous vein diameter greater than 3 mm and less than 12 mm in the standing position;\n* Only one limb per patient was selected for inclusion in the study;\n* Patients signed an informed consent form and were willing to co-operate in completing the protocol-specified investigations and follow-up visits.\n\nExclusion Criteria:\n\n* Thrombosis of the great saphenous or small saphenous vein, or combined deep vein thrombosis, or previous history of deep vein thrombosis or pulmonary embolism.\n* Recurrent varicose veins after previous treatment.\n* Severe distortion of the great saphenous vein with anticipated catheter failure.\n* Severe lower limb ischaemia (CLI) (ABPI \\\u003C0.8).\n* Known allergy to medications and device materials involved in the study.\n* Pre-existing implanted pacemaker, defibrillator, currently on regular anticoagulation therapy (e.g., warfarin, heparin).\n* Women who are pregnant or breastfeeding.\n* Unable or unwilling to complete the questionnaire.\n* Participating in a study of another drug or device.\n* Life expectancy \\\u003C1 year.\n* Those undergoing treatment for skin malignancies other than non-melanoma.\n* Daily use of narcotic drugs or non-steroidal anti-inflammatory drugs to control pain due to venous disease.\n* In the judgement of the investigator, endovenous therapy is not appropriate.","90 Years",{"count":164,"type":20},150,[23],"Objective: To investigate the clinical efficacy of ultrasound-guided radiofrequency ablation and microwave ablation in the treatment of primary saphenous varicose veins.",[120,26,121],[169,124,170],"varicose veins of the small saphenous veins","microwave ablation","2024-11-28",{"date":173,"type":36},"2024-12-02",{"date":175,"type":20},"2024-12-01",{"date":177,"type":20},"2025-12-01",{"name":134,"class":43},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":185,"targetDuration":187,"studyType":188,"phases":4,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":200,"leadSponsor":201,"locationsCount":44},"100569361","observation-of-pain-during-the-treatment-of-great-saphenous-vein-using-microwave-ablation-and-analysis-of-related-factors-100569361","NCT06693245","Observation of Pain During the Treatment of Great Saphenous Vein Using Microwave Ablation， and Analysis of Related Factors","Inclusion Criteria:\n\n1. Age≥ 18 years old, ≤ 90 years old;\n2. the patient's life expectancy is greater than 12 months;\n3. The clinical diagnosis is primary VVs, CEAP classification C2-C6, and the GSV segment needs to be treated, including pain, burning sensation, heaviness, fatigue, itchy skin, night cramps and other clinical symptoms;\n4. Doppler ultrasound confirmed that the diameter of GSV was greater than 3mm and less than 12mm when standing;\n5. Doppler ultrasound confirms that GSV is located in the saphenofascia or the distance between GSV and the skin surface is \\>1cm;\n6. endovenous microwave ablation treatment only for unilateral GSV walking area;\n7. The patient is willing to cooperate with the completion of the examination specified in the protocol.\n\nExclusion Criteria:\n\n1. GSV thrombosis, or combined with deep vein thrombosis, or previous history of deep vein thrombosis and pulmonary embolism;\n2. patients with recurrence after prior VVs-related surgery (C2r);\n3. the GSV trunk is severely distorted, and it is expected that the catheter will not be able to pass;\n4. Severe ischemia of the lower limbs, Ankle brachial pressure index (ABPI) \\\u003C 0.8;\n5. Known allergy to the drugs and device materials involved in the study;\n6. Previously implanted with a pacemaker or defibrillator, and currently receiving regular anticoagulation therapy (such as warfarin, heparin);\n7. Pregnant or lactating females;\n8. Patients who are unable or unwilling to participate in the study;\n9. Participating in the research of other drugs or devices;\n10. Skin malignancies other than non-melanoma that are being treated;\n11. daily use of narcotic drugs or non-steroidal anti-inflammatory drugs to control pain caused by venous disease;\n12. The investigator judged that endovenous treatment was not suitable;",{"count":186,"type":20},155,"1 Day","OBSERVATIONAL","Objective: This study is a single-center prospective observational research that recorded patients' pain scores at four time points during surgery (puncture and catheter insertion, swelling fluid injection, microwave generator operation, and end of surgery). It analyzed the correlation between pain during microwave ablation treatment for great saphenous vein varicosities and factors such as age, gender, body mass index, volume of swelling fluid used, and others, in order to summarize and improve surgical details to reduce patients' intraoperative pain.",[121,26,120],[192,193,194,195],"Varicose veins of the lower extremities","Endovenous Microwave Ablation","intraoperative pain","visual analogue scale of pain","2024-11-15",{"date":198,"type":36},"2024-11-18",{"date":175,"type":20},{"date":177,"type":20},{"name":134,"class":43}]